Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




A Subset of Immune T-Cells Protects Against Metabolic Syndrome in Mouse Model

By LabMedica International staff writers
Posted on 16 Nov 2015
A subset of immune T-cells lacking the lytic protein perforin was found to be responsible for inducing the onset of metabolic syndrome (obesity, high blood pressure, high levels of blood sugar and cholesterol) in mice fed a normal diet.

Investigators at the Weizmann Institute of Science (Rehovot, Israel) were seeking molecular clues that would clarify the emerging evidence that immunological mechanisms underlie metabolic control of adipose tissue.

To this end they used bone marrow transplantation to generate a line of mice that lacked the perforin-containing granules (perf-DCs) normally found in this subset of dendritic T-cells. More...
Perforin is a protein that creates transmembrane tubules and is capable of lysing non-specifically a variety of target cells. This protein is one of the main cytolytic proteins of cytolytic granules, and it is known to be a key effector molecule for T-cell- and natural killer-cell-mediated cytolysis.

The investigators reported in the September 15, 2015, online edition of the journal Immunity that the perforin-deficient mice progressively gained weight and exhibited features of metabolic syndrome. This phenotype was associated with an altered repertoire of T-cells residing in adipose tissue and could be completely prevented by T-cell depletion in vivo.

A similar impact of perf-DCs on inflammatory T-cells was also found in a well-defined model of multiple sclerosis, experimental autoimmune encephlalomyelitis (EAE). Thus, perf-DCs probably represent a regulatory cell subpopulation critical for protection from metabolic syndrome and autoimmunity.

Related Links:

Weizmann Institute of Science



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HPV Molecular Test
BD Onclarity HPV Assay
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.